Navigation Links
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
Date:12/10/2008

BASEL, Switzerland, Dec. 10 /PRNewswire/ -- New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue to offer new and better treatment options for breast cancer patients allowing women to live longer or remain disease-free for longer if the medicines are given before and after surgery as well as in advanced stages of disease.

    Key data being presented include:

    - Herceptin before surgery: Results from the NOAH (NeOAdjuvant Herceptin)
      phase III study showed that women with locally advanced HER2-positive
      breast cancer who started a combination of Herceptin and standard
      chemotherapy prior to surgery had a significantly greater chance of
      living free of their disease (event-free survival) three years after
      initiation of treatment as compared to women who were receiving pre-
      operative chemotherapy alone.

    - Xeloda in early breast cancer: Early data from an independent study in
      Finland and Sweden indicate that the chemotherapy pill Xeloda, which is
      already proven in advanced breast cancer, may also reduce the
      recurrence of early breast cancer and help women live longer. This is
      one of 20 Xeloda abstracts that have been accepted for presentation
      during SABCS.

    - Avastin in advanced breast cancer: First efficacy results from the
      largest ever safety study of Avastin in a real-life setting, which
      involved more than 2,000 patients with locally recurrent or metastatic
      breast cancer, confirm that Avastin can be used with a broad range of
      chemotherapy treatments giving patients a median of almost 10 months
      without their disease getting worse. The results, which are one of 24
      separate Avastin data presentations during SABCS, confirm that Avastin
      based therapy is essential for improving the li
'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
5. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
6. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
7. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... CHENGDU, China , Aug. 28, 2014 /PRNewswire/ ... TPI ), a pharmaceutical company that specializes ... branded generics and active pharmaceutical ingredients (API) today ... the Company,s Qionglai Facility (QLF). ... Manufacturing Practice (GMP) dataset for China Food & ...
(Date:8/28/2014)... SALT LAKE CITY , Aug. 28, 2014 /PRNewswire-iReach/ ... in 2000 by service academy graduates, has published a ... its concentrated, three-day Leadership Excellence Course . In ... the  Leadership Excellence Course to Albuquerque , ... Tucson . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
(Date:8/28/2014)... Aug. 28, 2014 Nonin Medical, Inc., the ... noninvasive medical monitoring, today announced that the Food and ... OEM/eHealth finger pulse oximeter for use in ... plugs into a telemedicine hub or kiosk through a ... in pediatric to adult patients. The Model 3231 received ...
Breaking Medicine Technology:TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... N.J., May 03, 2007 /PRNewswire-FirstCall/ --,Alpharma ... pharmaceutical company,through its Pharmaceuticals Division, this ... study of its investigational,abuse-deterrent, extended-release opioid ... the American Pain Society in Washington, ...
... /PRNewswire-FirstCall/ --,Genelabs Technologies, Inc. announced today that ... International Conference on Antiviral,Research being held in ... virus (HCV) polymerase inhibitor,discovered by Genelabs. , ... D. Roberts,Ph.D., Director of Medicinal Chemistry at ...
Cached Medicine Technology:Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 2Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 3Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 4Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 2Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 3
(Date:8/29/2014)... August 29, 2014 Senior Independence ... operations & business development. , Rees has been with ... of business development. , A wholly owned subsidiary of ... provides older adults with options, including personalized home health ... (e.g., meal preparation) and therapeutic adult day centers. , ...
(Date:8/29/2014)... 29, 2014 Los Angeles dental ... mini implants to area patients. With this treatment, patients ... long-term teeth shifting and loss of appearance. Although mini ... implants , their smaller size allows for less ... easier recovery. Once placed, mini implants can be topped ...
(Date:8/29/2014)... A home should be a safe haven, but there ... Amica Insurance is sharing some tips to help improve safety in ... following safety measures: , Kitchen, , Store hazardous ... and keep them away from food. , ... , Bathroom , Put slip-resistant ...
(Date:8/29/2014)... life support (BLS) videos available on YouTube provide ... according to a new study published in ... Australasian College for Emergency Medicine (ACEM). , ... are known to improve survival for,victims. , A ... the study, which reviewed educational videos from the ...
(Date:8/29/2014)... Saturday 30 August 2014: New ESC registries ... coronary syndromes (ACS). The announcement comes as the ... and the study on heart failure patients conducted ... and Development (OECD) begins an outcomes evaluation. , ... EURObservational Research Programme (EORP). , Professor Roberto Ferrari, ...
Breaking Medicine News(10 mins):Health News:Senior Independence Promotes Rees to Vice President of Operations & Business Development 2Health News:Dental Implants Dentist, Kevin Sands DDS, Is Now Offering Mini Implants 2Health News:Improve Home Safety with Tips from Amica Insurance 2Health News:New ESC registries launched on cardiac oncology and ACS 2Health News:New ESC registries launched on cardiac oncology and ACS 3Health News:New ESC registries launched on cardiac oncology and ACS 4
... ... of software & technology to Home Medical Equipment, Durable Medical Equipment, Respiratory ... a solution for each individual segment of Home Care as well as ... provider offering several or all of these product/service lines within one integrated ...
... ... interactive database on tap water quality. The data has been compiled from state environment ... concerning the database. , ... Washington (Vocus) December 11, 2009 -- On December 12, 2009, the Environmental Working ...
... 11 They feature real patients, real stories and ... campaign titled "Real Patients, Real Stories" won Platinum in ... event held in Chicago this fall. , Baylor teamed ... the non-traditional spots. The documentary-style ads feature actual patients ...
... sensory problems before onset of complex disease symptoms benefits ... -- Identifying sight and hearing problems in teens who ... doctors fully restore those senses and lessen the impact ... A new study found that problems in basic sensory ...
... A gene commonly studied by cancer researchers has been linked ... Understanding how the gene works means scientists may be ... a study by Texas AgriLife Research appearing in the Journal ... understand the mechanism, or how the gene works, we believe a ...
... The Visiting Nurse Association (VNA) of Greater Philadelphia is ... who reside in lower Bucks County. , The ... wound and ostomy care, and chronic care services. Nurses, ... to patients in their homes. , VNA also ...
Cached Medicine News:Health News:Fastrack Announces Enhancements to the Enterprise System for Home Care 2Health News:Statement from American Water Works Association on the Environmental Working Group's report on Tap Water Quality Testing and Violations 2Health News:Baylor Health Care System's Patient Testimonial Ad Campaign Wins National Award 2Health News:Early Treatment of Hearing, Vision Helps in Schizophrenia 2Health News:Study shows how gene action may lead to diabetes prevention, cure 2Health News:The Visiting Nurse Association of Greater Philadelphia Expands Service to Bucks County 2
Inquire...
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies....
Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels....
... APTT-based kit for the screening of factor-V-related ... of the test for the factor V:Q506 ... plasma with an excess of V-DEF Plasma ... to discriminate between heterozygous and homozygous factor ...
Medicine Products: